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Abstract
Background: Erythropoietin (EPO), a hematopoietic cytokine, enhances neurogenesis and angiogenesis during stroke
recovery. In the present study, we examined the effect of EPO on oligodendrogenesis in a rat model of embolic focal
cerebral ischemia.
Methodology and Principal Findings: Recombinant human EPO (rhEPO) at a dose of 5,000 U/kg (n=18) or saline (n=18)
was intraperitoneally administered daily for 7 days starting 24 h after stroke onset. Treatment with rhEPO augmented
actively proliferating oligodendrocyte progenitor cells (OPCs) measured by NG2 immunoreactive cells within the peri-infarct
white matter and the subventricular zone (SVZ), but did not protect against loss of myelinating oligodendrocytes measured
by cyclic nucleotide phosphodiesterase (CNPase) positive cells 7 days after stroke. However, 28 and 42 days after stroke,
treatment with rhEPO significantly increased myelinating oligodendrocytes and myelinated axons within the peri-infarct
white matter. Using lentivirus to label subventricular zone (SVZ) neural progenitor cells, we found that in addition to the
OPCs generated in the peri-infarct white matter, SVZ neural progenitor cells contributed to rhEPO-increased OPCs in the
peri-infarct area. Using bromodeoxyuridine (BrdU) for birth-dating cells, we demonstrated that myelinating oligodendro-
cytes observed 28 days after stroke were derived from OPCs. Furthermore, rhEPO significantly improved neurological
outcome 6 weeks after stroke. In vitro, rhEPO increased differentiation of adult SVZ neural progenitor cells into
oligodendrocytes and enhanced immature oligodendrocyte cell proliferation.
Conclusions: Our in vivo and in vitro data indicate that EPO amplifies stroke-induced oligodendrogenesis that could
facilitate axonal re-myelination and lead to functional recovery after stroke.
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Introduction
Oligodendrocytes are the myelin-forming glial cells in the adult
brain and are highly vulnerable to ischemic insult [1,2,3]. Garcia
and his colleagues demonstrate that as early as 30 minutes after
middle cerebral artery occlusion (MCAo), animals exhibit swelling
of oligodendrocytes followed by white matter injury [2].
Regeneration of mature oligodendrocytes has been observed in
the peri-infarct areas after stroke [4,5]. Mature oligodendrocytes in
adult rodent brain are derived from non-myelinating oligoden-
drocyte progenitor cells (OPCs) that are present in the corpus
callosum and the striatum [6,7] Neural progenitor cells in the
subventricular zone (SVZ) of the lateral ventricles also give rise to
OPCs that disperse throughout the corpus callosum and striatum
[8]. Mature oligodendrocytes in the ischemic boundary are likely
generated from the OPCs because mature oligodendrocytes are
generally considered incapable of cell division [9,10,11]. There are
a paucity of studies that have investigated regeneration of
oligodendrocytes in the ischemic brain during long-term stroke
recovery [12]. Understanding of how OPCs and new oligoden-
drocytes contribute to ischemic repair is important for the
development of therapies aimed at facilitating generation of
mature oligodendrocytes that could promote remyelination
leading to functional improvement after stroke.
Erythropoietin (EPO), a hematopoietic cytokine, facilitates
oligodendrocyte maturation in vitro [13]. In experimental models
of multiple sclerosis, spinal cord injury, cortical infarction, and
neonatal hypoxia-ischemia, EPO treatment increases OPC
proliferation and myelinating oligodendrocytes [14,15,16,17]. In
the current study, we investigated the effect of EPO on
oliogdendrogenesis in a rat model of embolic stroke.
Results
The effect of EPO on functional outcome and infarct
volume
To test the restorative effect of recombinant human EPO
(rhEPO) on stroke, rhEPO (5,000 units/kg) was intraperitoneally
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Neurological deficits were examined before the treatment and 2
and 6 weeks after stroke by means of modified neurological
severity score (mNSS) and foot-fault test. All rats exhibited severe
deficits measured by mNSS and foot-fault test 24h after middle
cerebral artery (MCA) occlusion and there were no significant
differences among the groups (Fig. 1). Although rats treated with
saline exhibited spontaneous improvements of behavioral out-
comes, treatment with rhEPO significantly (P,0.05) improved
neurological outcome compared with saline treated rats 6 weeks
after stroke (Fig. 1), which is consistent with published studies
[18,19]. The ischemic lesion was not significantly (P.0.05)
different between rats treated with saline (32.864.4% of the
contralateral hemisphere) and rhEPO (34.465.6%).
The effect of EPO on OPCs and myelinating
oligodendrocytes in the ischemic brain
Aforementioned data suggest that the effect of EPO on
improvement of functional outcome is not primarily resulted from
the neuroprotective effect. To examine the effect of EPO on
oligodendrocytes in the ischemic brain, we measured OPCs and
myelinating oligodendrocytes 7, 28 and 42 days after embolic
ischemia. OPCs were identified by NG2 positive cells, while
myelinating oligodendrocytes were detected by cyclic nucleotide
phosphodiesterase (CNPase) or myelin basic protein (MBP)
immunoreactive cells [20]. CNPase immunostaining revealed that
7 days after MCAo, CNPase immunoreactivity was essentially
absent in the striatal ischemic core (Fig. 2C) compared with the
CNPase immunoreactivity in the contralateral striatum (Fig. 2B),
indicating substantial loss of myelinating oligodendrocytes.
Treatment with rhEPO did not increase ipsilateral CNPase
immunoreactivity (28.661.8%, n=4) compared with the saline
group (27.762.9%, n=4) 7 days after MCA occlusion. In contrast
to the loss of CNPase immunoreactivity, there were many NG2
positive cells in the ischemic boundary region and the SVZ 7 days
after MCAo (Fig. 2I-L). Double immunostaining revealed that
many NG2 positive cells in these two regions were proliferating
cell nuclear antigen (PCNA) positive, a proliferation marker that
labels cells in the active cell cycle (Fig. 2I-L), indicating that these
NG2 positive cells are within the cell cycle [21,22]. Animals
treated with rhEPO had a significant increase in the number of
NG2 positive cells in the peri-infarct corpus callosum and striatum
and the SVZ compared with the rats treated with saline (Fig. 2M-
P), suggesting that at this stage, EPO amplifies the number of
OPCs in both regions.
The adult SVZ generates OPCs that disperse throughout the
corpus callosum and striatum [8]. To examine whether stroke
recruits OPCs from the SVZ, SVZ cells were labeled with the
green fluorescent protein (GFP)-lentivirus 3 days prior to stroke,
and these rats were sacrificed 7 days after MCAo. In non-ischemic
rats, GFP-lentivirus labeled cells were detected within the SVZ
one week after injection of the vector (data not shown). However,
in the ischemic rats, GFP-positive cells were detected in the peri-
infarct regions and some of the GFP-positive cells were NG2
immunoreactive (Fig. 3). Treatment with rhEPO significantly
increased the number of GFP and NG2 positive cells in the peri-
infarct corpus callosum and striatum compared with rats treated
with saline (Fig. 3), suggesting that EPO mobilized OPCs from the
SVZ to the peri-infarct corpus callosum and striatum.
Twenty-eight and 42 days after MCAo, ischemic rats treated
with rhEPO exhibited a significant increase in CNPase and MBP
immunoreactivity along the peri-infarct corpus callosum and
striatum compared to the ischemic rats treated with saline (Fig. 2
and 4). To examine whether CNPase immunoreactive cells
observed 28 days after MCAo are derived from OPCs, we
injected bromodeoxyuridine (BrdU) for 7 days starting 1 day after
MCAo, which labels proliferating cells during this period, and
sacrificed these animals 28 days after ischemia. If proliferating
OPCs labeled by BrdU differentiate into myelinating oligoden-
drocytes during 21 days after BrdU injection, the cells labeled with
BrdU will exhibit phenotypes of myelinating oligodendrocytes.
Indeed, BrdU and CNPase immunoreactive cells were detected in
the ischemic boundary region and confocal images revealed co-
localization BrdU in the nucleus and CNPase in the cytoplasm of
the same cell (Fig. 4O-R). Some CNPase positive cells exhibited
faint BrdU immunoreactivity, suggesting that the OPCs labeled
with BrdU continue to divide before differentiation into myelinat-
ing oligodendrocytes. These data indicate that new myelinating
oligodendrocytes are derived from the OPCs. Quantitative data
analysis shows that rhEPO treatment substantially increased the
percentage of CNPase cells reactive to BrdU (12.562.1%, n=5)
compared with the rats treated with saline (5.361.6%, n=7) 28
days after stroke, suggesting that EPO enhances generation of new
myelinating oligodendrocytes.
Figure 1. Neurological functional outcome. Panels A and B show the neurological functional outcome measured by mNSS (A) and foot-fault test
(B) 1, 14, and 42 days after MCAo. Values are mean 6 SE. *P,0.05 as compared with the saline-treated group.
doi:10.1371/journal.pone.0011016.g001
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(green box in A) and ipsilateral SVZ (green arrowhead in A) where all representative microscopic images were acquired. The yellow color represents
ischemic core, and the red color indicates peri-infarct region. Panels B to H show CNPase immunoreactivity of representative rats treated with saline
(B, C, E, F) and rhEPO (D, G, H), which were acquired from ipsilateral (C to H) and contralateral (B) striatum 7d (B to D) and 28d (E to H) after stroke.
Panels F and H are high magnification images from boxed areas in panels E and G, respectively. Panels I to L show the double fluorescence
immunostaining of NG2 (red) with PCNA (green), from representative rats treated with saline (I, J) and rhEPO (K, L), which were acquired from peri-
infarct striatum (I, K) and SVZ (J, L). Panels M and O are the quantitative data of NG2 positive cells in peri-infarct corpus callosum and striatum (M), and
ipsilateral SVZ (O). Panels N and P are the quantitative data of NG2 and PCNA double positive cells in peri-infarct corpus callosum and striatum (N),
and ipsilateral SVZ (P). Values are mean 6 SE. *P,0.05 vs saline.
+P,0.05 vs the 7 day group. IBZ = ischemic boundary zone, CC = corpus callosum;
Ctx = cortex; IC = ischemic core; LV = lateral ventricle; Str = striatum; SVZ = subventricular zone. Scale bars: 100 mm for panels B, C, D, E, and G,
50 mm for panels F and H. For 7 days, n=4/saline and n=4/rhEPO; for 28 days, n=7/saline and n=5/rhEPO; for 42 days, n= 7/saline and n=9/rhEPO.
doi:10.1371/journal.pone.0011016.g002
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NG2 positive cells in the peri-infarct region and the SVZ
decreased 28 and 42 days after MCAo compared with the
number at 7 days after stroke (Fig. 2). However, ischemic rats
treated with rhEPO exhibited a significantly higher number of
NG2 positive cells than rats treated with saline 28 and 42 days
after stroke (Fig. 2). Quantitative analysis shows that many NG2
positive cells were PCNA positive (Fig. 2), indicating that even 42
days after stroke, OPCs actively proliferate.
The effect of EPO on axons in the ischemic brain
Our observation that rhEPO increased mature oligodendro-
cytes prompted us to examine the effect of EPO on myelinated
axons. We performed Bielschowsky and Luxol fast blue staining
which detects myelinated axons and neurofilament-H (NF-H)
immunostaining which labels axons [14]. Seven days after MCAo,
NF-H positive axons appearing swollen and bulbous were present
in the ischemic striatum and these axons were not surrounded by
CNPase immunoreactivity (Fig. 4). Bielschowsky and Luxol fast
staininig shows loss of myelinated axons in the ischemic striatum
(Fig. 4). These data are consistent with published findings that
ischemia directly injures axons [23]. Treatment with rhEPO did
not significantly preserve NF-H positive axons compared with the
saline treatment 7 days after MCAo (Fig. 4). However, 28 and 42
days after MCAo, ischemic rats treated with rhEPO had a
significantly higher density of NF-H immunoreactivity and
Bielschowsky and Luxol fast blue positive axons in the striatal
ischemic boundary region than ischemic rats treated with saline
(Fig. 4). Double immunostaining revealed that CNPase immuno-
reactive structures were adjacent to NF-H immunoreactive axons
in the ischemic boundary region (Fig. 4). These data suggest that
EPO enhances myelinated axons.
The effect of EPO on generation and maturation of OPCs
in vitro
To verify our in vivo findings, we performed in vitro experiments
using primary SVZ cells harvested from the adult rat and an
oligodendrocyte cell line (N20.1). Adult rodent SVZ cells contain
oligodendrocyte progenitor cells that migrate into the white matter
[8,24,25,26,27,28]. Incubation of SVZ cells with rhEPO signifi-
cantlyincreasedthenumberofO4positivecellsina dosedependent
manner with a maximum increase at 10 units/ml(Fig. 5),suggesting
that EPO enhances generation of oligodendrocyte progenitor cells.
In addition to the SVZ, many OPCs are present in white matter
[29,30]. We thus incubated immature oligodendrocyte cells (N20.1
cells) with rhEPO and found that rhEPO at concentrations of 5
and 10 units/ml significantly increased the percentage of BrdU
immunoreactive N20.1 cells (Fig. 5), indicating that EPO promotes
immature oligodendrocyte proliferation.
Discussion
The present study demonstrates that administration of rhEPO
24 h after embolic MCAo induced sustained OPC proliferation in
the peri-infarct white matter and the SVZ. In addition, rhEPO
treatment substantially amplified myelinating oligodendrocytes
Figure 3. Effects of EPO on the recruitment of OPCs from the SVZ. Panels A to C show GFP (green) and NG2 (red) immunoreactive cells in peri-
infarct striatum from a representative rat treated with rhEPO 7 days after stroke. Some of GFP positive cells that were labeled in the SVZ 3 days prior to
strokewereNG2 immunoreactive (arrows) inthe peri-infarctarea. Quantitativedatashowthatthe rhEPOtreatmentsignificantly increased number ofGF P
labeled cells (D) and percentage of NG2 positive GFP labeled cells (E) compared with the saline-treated group. *P,0.05 vs saline. Scale bars=100 mm.
doi:10.1371/journal.pone.0011016.g003
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which was associated with substantial improvement of functional
outcome 6 weeks after stroke. These data suggest that EPO
amplifies stroke-induced oligodendrogenesis and axonal remodel-
ing that may contribute to functional recovery after stroke.
Oligodendrocytes are the myelin-forming glial cells in the adult
brain [1]. In the current study, the loss of mature oligodendrocytes
occurred at the peri-infarct white matter 7 days after MCAo,
which is consistent with previous studies showing that the
oligodendrocytes are highly susceptible to ischemic insults [2,3].
Mature oligodendrocytes do not proliferate [9,10] and new
oligodendrocytes are derived from non-myelinating OPCs that
are present in the corpus callosum and the striatum [6,7,31].
Neural progenitor cells in the SVZ also give rise to nonmyelinating
OPCs that disperse throughout the corpus callosum and striatum
[8]. Stroke induces generation of OPCs and new oligodendrocytes
[5]. However, sources of OPCs and differentiation of OPCs to new
oligodendrocytes have not been fully examined. The present study
demonstrated that SVZ cells labeled with GFP prior to stroke
exhibited a phenotype of OPCs in the peri-infarct region 7 days
after stroke. Using BrdU labeling for birth-dating cells, we show
that actively proliferating OPCs differentiated into myelinating
oligodendrocytes as measured by CNPase positive cells. Collec-
tively, these data suggest that in addition to OPCs in white matter,
stroke recruits SVZ neural progenitor cells that contribute to the
generation of new oligodendrocytes in peri-infarct white matter,
which is consistent with findings that neural progenitor cells
originating from the SVZ contribute to white matter oligoden-
drogenesis after demyelination [8,32]. More importantly, our in
vivo and in vitro data indicate that exogenous EPO substantially
amplifies stroke-induced oligodendrogenesis from both sources.
However, additional experiments are warranted to examine
Figure 4. Effects of EPO on axons and myelinating oligodendrocytes. Panels A to L show the double fluorescence immunostaining of NF-H
(green, A, C, E, G, I, and K) with CNPase (red, B, C, F, G, J, and K), and Bielschowsky and Luxol fast blue staining (D, H, and L) from representative rats
treated with saline (A to D, at 7d; E to H, at 42d) and rhEPO (I to L, at 42d), which were acquired from ipsilateral striatum. An arrow in panels A to C
indicate NF-H positive axons with appearances of swellings and bulbs (green) that were not associated with CNPase immumoreactivity (red) 7d after
stroke. Quantitative data show that rhEPO treatment significantly increase NF-H immunoreactivity (M) and Bielschowsky and Luxol fast blue (N)
positive axons in the peri-infarct striatum compared with saline treated rats 28 and 42d after stroke. Confocal microscopic images (O to R) show that a
CNPase immunoreactive cell (red, arrow) was BrdU positive (green, arrow) in the nucleus (DAPI, blue, arrow) of a representative rat treated with rhEPO
28d after stroke. Quantitative data shows that treatment with rhEPO significantly increases the CNPase (S) and MBP (T) immunoreactive area 28 and
42d after stroke. Values are mean 6 SE. IC, ischemic core. Scale bars: 50 mm for panels A to L, 20 mm for panels E to H. IC = ischemic core. For 7 days,
n=4/saline and n=4/rhEPO; for 28 days, n=7/saline and n=5/rhEPO; for 42 days, n=7/saline and n=9/rhEPO.
doi:10.1371/journal.pone.0011016.g004
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OPC proliferation. A few studies have examined the effect of EPO
on oligodendrocytes after cerebral ischemia [16,17,33,34]. Ad-
ministration of rhEPO immediately after hypoxia-ischemia in the
neonatal rat does not protect against white matter damage
measured 72 h after hypoxia-ischemia [33]. In a mouse model of
cortical injury, administration of rhEPO immediately after injury
significantly increased the number of CNPase and MBP positive
cells assayed 11 months after the injury [16]. In parallel, the
present study shows that treatment with rhEPO did not prevent
loss of mature oligodendrocytes but significantly increased the
number of OPCs 7 days after stroke, while treatment with rhEPO
substantially increased myelinating oligodendrocytes at the
ischemic boundary 28 and 42 days after stroke, indicating that
EPO likely acts on oligodendrogenesis rather than on protecting
oligodendrocytes. Our data are supported by a very recent study
showing that delayed administration of rhEPO promotes oligo-
dendrogenesis and improves neurological functional recovery after
neonatal hypoxic/ischemic brain injury [17].
Studies in CNPase knockout mice indicate that CNPase
expressing cells are required to support axonal integrity [35].
Our data show that EPO-increased CNPase immunoreactivity was
closely associated with NF-H positive axons and that EPO
augmented myelinated axons measured by Bielschowsky and
Luxol fast blue positive axons. Interestingly, using in vivo
measurement of diffusion anisotropy which detects axonal tract
integrity within white matter after stroke [36], we previously
demonstrated that treatment with rhEPO enhanced axonal
density around peri-infarct region starting 4 weeks, a time point
when a substantial increase in CNPase immunoreactivity was
detected in the present study [37]. Thus, we speculate that EPO-
amplified oligodendrogenesis facilitates axonal remodeling in the
ischemic boundary region, which contributes improvement of
functional outcome.
NG2 positive cells are generally considered as OPCs, although
NG2 can be induced in activated microglia [5,38,39,40,41]. NG2
positive cells rapidly proliferate in response to ischemia
[5,38,39,40,41]. In addition to their role as OPCs, NG2 positive
cells maintain the extracellular microenvironment of neurons,
both in the white and the grey matter [42], and a subpopulation of
NG2 positive cells exhibit characteristics of neural progenitor cells
[43]. Thus, sustained actively proliferating NG2 positive cells
increased by EPO may play additional and as yet unidentified
important roles in brain repair after stroke, which warrant further
investigation.
Materials and Methods
All experimental procedures were carried out in accordance
with the NIH Guide for the Care and Use of Laboratory Animals
and approved by the Institutional Animal Care and Use
Committee of Henry Ford Hospital (IACUC approval number:
0811).
Animal model
Male Wistar rats weighing 350–400 g were subjected to embolic
MCA occlusion, as previously described [44].
Experimental protocols
To test the effect of rhEPO on stroke, rhEPO at a dose of 5,000
units/kg was intraperitoneally administered daily for 7 days
starting 24 h after stroke onset (n=18). As a control group, the
same volume of saline was administered to ischemic rats (n=18)
with the identical protocol described above. For mitotic labeling,
BrdU (100 mg/kg) was administered daily for 7 days starting 24 h
after stroke onset.
Lentiviral labeling: To examine whether SVZ neural progenitor
cells migrate to the ischemic boundary region, SVZ cells were
labeled with a lentivirus-GFP vector that was constructed, as
previously described [45,46]. Briefly, subconfluent human embry-
onic kidney 293T cells (ATCC) were cotransfected with 20 mgo fa
lentiviral vector LV-TH, 15 mg of pCMV-DR8.91, and 5 mgo f
pMD2G-VSVG vectors, After 16 h, the medium was changed,
and recombinant lentivirus vectors were harvested 24 h later [46].
For SVZ injection, rats were placed under anesthesia on a Koft
stereotaxic apparatus. 5 ml lentivirus-GFP vector was injected into
the right SVZ at the coordinates of 1.0 mm lateral to the midline,
anterior-posterior at the zero point to the bregma, and 4.5 mm in
depth [47] over a 10 min period. The needle was left in the SVZ
for an additional 5 min before retraction to avoid reflux. These
Figure 5. Effects of EPO on generation of OPCs in vitro. Fluorescent microscopic images show O4 (A and B, red) and BrdU (D and E, red)
immunoreactive cells in SVZ neural progenitor cells (A and B) and N20.1 cells (D and E), respectively, in the presence (B and E) or absence (A and D) of
rhEPO. Panels C and F show quantitative data of O4 positive cells in SVZ neural progenitor cells (C) and BrdU positive cells in N20.1 cells (F) at different
concentrations of rhEPO. Blue color represents DAPI positive nuclei. Values are mean 6 SE. *P,0.05 vs the control group. Scale bars=20 mm.
doi:10.1371/journal.pone.0011016.g005
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the lentivirus-GFP vector injection. rhEPO at a dose of 5,000
units/kg was intraperitoneally administered daily for 7 days
starting 24 h after stroke onset (n=4). Saline treated rats were
served as a control group (n=4).
Functional outcome
All functional outcome tests were performed by observers
blinded to the treatments 1, 14, and 42 days after onset of MCA
occlusion.
Modified neurological severity score (mNSS)
Rats were tested for motor, sensory, reflex, and balance
dysfunctions with the mNSS [48]. Neurological function was
graded on a scale of 0 to 18 (normal score, 0; maximal deficit
score, 18).
Foot-fault test
A modified foot-fault test was employed to measure forelimb
placement dysfunction [49]. The total number of steps (movement
of each forelimb) that the rat used to cross the grid and the total
numbers of foot faults for left forelimb were recorded.
Histopathology and immunohistochemistry
Rats were sacrificed 7, 28 or 42 days after stroke. The brains
were removed and consecutive coronal sections at bregma -0.4 to -
1.4 mm were prepared. Infarct volume was measured on 7
hematoxylin and eosin (H&E) stained coronal sections using the
microcomputer imaging device (MCID) system (Imaging Re-
search, St. Catharines, Ontario, Canada), as previously described
[44].
OPCs were identified by staining with antibodies against NG2
(1:800, Chemicon) and O4 (1:100, Chemicon). CNPase is a
prenylated myelin protein and MBP is an abundant protein
component of the myelin sheath, which are highly expressed in
mature oligodendrocytes [50,51]. For evaluation of myelinating
oligodendrocytes, an antibody against CNPase (Chemicon) was
used at a titer of 1:200 and an antibody against MBP (Abcam) was
used at a titer of 1:1000. Double immunostaining of CNPase and
BrdU (Boehringer Mannheim; 1:1000) was performed to identify
the BrdU incorporating oligodendrocytes. To identify proliferating
OPCs, double immunostaining of NG2 and PCNA was per-
formed. Double immunostaining of NF-H (1:10000; ABR) and
CNPase was performed to identify the relationship of axons and
oligodendrocytes, respectively. To identify GFP–labeled SVZ cells
and their phenotypes, double immunostaining with antibodies
against GFP (1:500, Chemicon) and NG2 (1:800, Chemicon) was
performed on frozen sections obtained from ischemic rats injected
with the lentivirus-GFP vector. Double immunolabeling was
visualized by secondary antibodies conjugated to FITC and Cy3
(Vector). Bielschowsky and Luxol fast blue staining was also used
to detect axons and myelin, respectively [14].
Image acquisition and quantification
Five coronal sections (8 mm/section) spaced as 100 mm intervals
per staining were used from each rat and these coronal sections
were within the territory supplied by the MCA at bregma 20.4 to
21.4 mm [44]. Each coronal section was digitized using a 40x
objective via MCID system. For quantification of axons and
myelinating oligodendrocytes, NF-H, CNPase, MBP, and
Bielschowsky and Luxol fast blue positive areas were digitized
throughout the peri-infarct corpus callosum and striatum, as well
as the contralateral homologous area. Data are presented as the
percentage of immunoreactive area at the peri-infarct corpus
callosum and striatum compared with the contralateral homolo-
gous region on the same section. For quantitative analysis of
OPCs, the numbers of NG2 immunoreactive cells were counted
throughout the ipsilateral SVZ of the lateral ventricle and peri-
infarct area at the corpus callosum and striatum. The number of
positive cells for the 5 coronal sections per rat was averaged to
obtain a mean number of cells. Data are presented as the density
of immunoreactive cells relative to the area of the SVZ and peri-
infarct corpus callosum and striatum.
Coronal sections double stained with antibodies against NF-H
and CNPase or MBP were imaged using Zeiss confocal
microscopy (Zeiss LSM 510 NLO).
Rat SVZ and mouse N20.1 cell culture
To directly test whether EPO regulates oligodendrogenesis,
neural progenitor cells were isolated from the SVZ of adult rats
(n=3), as previously described [52]. To generate neurospheres,
SVZ cells were plated at a density of 2610
4 cells/ml in the
presence of growth medium [52]. The generated neurospheres
(primary sphere) were passaged by mechanical dissociation and
then plated directly onto laminin-coated glass coverslips in
Dulbecco’s modified Eagle’s (DMEM)-F12 medium containing
2% fetal bovine serum (FBS), but without the growth factors.
Passage 1 cells were used in the present study. To examine
whether rhEPO enhances oligodendrogenesis, neural progenitor
cells were treated with rhEPO at concentrations of 1, 5, and 10
units/ml (epoietina; Amgen) for 7 days. The cells in the medium
without rhEPO were used as a control group. Immunocytochem-
istry of O4 was performed to identify OPCs. Nuclei were
counterstained with 49,6 9-diamidino-2-phenylindole (DAPI,
Vector Laboratories). The number of O4 positive cells and total
DAPI cell number were counted and the percentage of O4 positive
cells was determined.
To further investigate the effect of EPO on oligodendrocyte cell
proliferation, we employed a mouse premature oligodendrocyte
cell line (N20.1, generously provided by Dr. Anthony Campag-
noni, University of California at Los Angeles), which was obtained
from mouse primary cultures of oligodendrocytes conditionally
immortalized by transformation with a temperature-sensitive large
T-antigen [53]. N20.1 cells grow in DMEM-F12 with 1% FBS
and and G418 (100 mg/ml) at 39uC. N20.1 cells were incubated
with or without rhEPO at concentrations of 1, 5, and 10 units/ml
for 24h, and 20 mg/ml BrdU (Sigma) was added to the cell cultures
for 1 h. Immunocytochemistry of BrdU was performed to identify
N20.1 cell proliferation. The number of BrdU positive cells and
total cell number were calculated by counting 10 random fields in
each well with 3 wells per group. The results are presented as a
percentage (positive cells divided by total cells).
Statistics
Data were evaluated for normality. Behavioral data were
evaluated with one-way analysis of variance (ANOVA) followed by
Student-Newman–Keuls test. Two sample t-tests were used to
compare the group difference on histological outcome if data were
normal, otherwise nonparametric (Wilcoxon) test was considered.
Statistical significance was set at P,0.05. All values are presented
as mean 6 SE.
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